Clazosenta (Ro 61-1790, VML-588 and AXV-034) is a novel and highly potent endothelin A antagonist which improves cerebral blood flow and behavior after traumatic brain injury. Clazosentan is being developed in clinical trials for the treatment of patients with aneurysmal subarachnoid hemorrhage (SAH) by Actelion Pharmaceuticals.Clazosentant decreases and reverses cerebral vasospasm after experimental SAH. Clazosentanthas been shown to reduce vasospasm after aneurysmal subarachnoid hemorrhage (aSAH).

纯度：≥98%

CAS：180384-56-9